PDL ZENAPAX HEADS INTO PHASE III: STOCK HEADS UP IN APRIL, ADVANCING 4-3/4 POINTS
Executive Summary
Protein Design Labs reports of clinical progress in development of its SMART humanized anti-Tac monoclonal antibody Zenapax for prevention of acute renal transplant rejection helped the stock gain 4-3/4 points (23.6%) in April to close at 24-7/8